Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival

• Published in: Asia-Pacific journal of clinical oncology Vol. 15; no. 3; pp. 136 - 143
• Main Authors: Mendis, Shehara, Beck, Sophie, Lee, Belinda, Lee, Margaret, Wong, Rachel, Kosmider, Suzanne, Shapiro, Jeremy, Yip, Desmond, Steel, Simone, Nott, Louise, Jennens, Ross, Lipton, Lara, Burge, Matthew, Field, Kathryn, Ananda, Sumitra, Wong, Hui‐Li, Gibbs, Peter
• Format: Journal Article
• Language: English
• Published: Australia Wiley Subscription Services, Inc 01.06.2019
• Subjects: Cancer; Cancer therapies; Chemotherapy; colonic neoplasms; Colorectal cancer; Colorectal carcinoma; Medical prognosis; Metastases; Metastasis; Mismatch repair; Multivariate analysis; Peritoneum; proportional hazards models; rectal neoplasms; Rectum; registries; Spleen; Survival; Tumors; rectal neoplasms; colonic neoplasms; registries; multivariate analysis; proportional hazards models
• ISSN: 1743-7555; 1743-7563
• DOI: 10.1111/ajco.13135

Background Metastatic colorectal cancer (mCRC) patients with a right‐sided primary (RC) have an inferior survival to mCRC arising from a left‐sided primary (LC). Previous analyses have suggested multiple factors contribute. Methods The Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) Registry prospectively captured data on consecutive mCRC patients. RC were defined as tumors proximal to the splenic flexure; LC were those at and distal to the splenic flexure and included rectal cancers. Patient, tumor, treatment, and survival data were analyzed stratified by side. Results Of 2306 patients enrolled from July 2009–March 2018, 747 (32%) had an RC. Patients with RC were older, more likely to be female and have a Charlson score ≥3. RC were more frequently BRAF mutated, deficient in mismatch repair, associated with peritoneal metastases, and less likely to receive chemotherapy. Progression‐free survival on first‐line systemic therapy was inferior for RC patients (8.1 vs. 10.8 months, hazard ratio [HR] for progression in RC 1.38, P < 0.001). Median overall survival for all RC patients was inferior (19.6 vs. 27.5 months, HR for death in RC 1.44, P < 0.001), and inferior within the treated (21 vs. 29.5 months, HR 1.52, P < 0.001) and untreated subgroups (5.9 vs. 10.3 months, HR 1.38, P = 0.009). Primary side remained a significant factor for overall survival in multivariate analysis. Conclusion Our data from a real‐world population confirms the poorer prognosis associated with RC. Primary tumor location remains significantly associated with overall survival even when adjusting for multiple factors, indicating the existence of further side‐based differences that are as yet undefined.